March 2018 ICT Results European Commission CORDIS
Hearing loss to the point of disability affects millions with enormous socio-economic costs.
The inner ear is extremely sensitive and can be functionally impaired by noise trauma, toxic drugs, infections, genetic causes and age-related degeneration. Hearing impairment - the most frequent human sensory deficit – is mainly caused by damage or loss of sensory hair cells in the cochlea of the inner ear (in the organ of Corti) that send ‘sound’ signals to the brain.
Scientists of the EU-funded OTOSTEM project coordinated by Prof. Löwenheim in Tübingen, wished to address this urgent medical issue by developing drug and cell-based therapies. “Our focus was set on stem cell technology to generate human inner ear models,″ explains deputy project coordinator Dr Hasan Avci. OTOSTEM tested two therapeutic approaches to treat hearing loss: A cell-based treatment introducing stem/otic progenitor cells into the cochlea, and a drug-based treatment to protect or regenerate sensory hair cells.
Researchers utilised various stem cell sources to obtain otic progenitor cells (OPCs). The generated OPCs had to fulfil certain criteria such as in vitro expansion and differentiation into sensory hair cells, supporting cells or otic neuronal cell types. Functionality of the generated otic or neuronal cell types was validated in in vitro experiments. Electrophysiological monitoring demonstrated that transplanted cells resembled those of mouse cochlear hair cells. Human otic neuronal progenitors were tested in preclinical animal models of auditory neuropathy. Hearing restoration was achieved and preserved for more than 30 weeks after transplantation with no adverse effects.
Hearing loss in a dish model
Currently, there is no quantitative cell-based testing of drugs for ototoxicity in humans, thus even approved drugs bear the risk of causing hearing loss. To address this, and facilitate drug safety studies, the OTOSTEM consortium designed drug screening assays. This ‘hearing loss in a dish model’ employed otic progenitor cell-like cells derived from human induced pluripotent stem cells. The human assay was used for medium-throughput testing of more than 2000 pharmacological active compounds including FDA-approved drugs. Surprisingly, several of these drugs were identified to be ototoxic.
Given the association of hearing impairment with neurodevelopment in young, and dementia in older people, there is an imminent unmet need for clinically validated therapies. Industrial partners envisage that the OTOSTEM models can be incorporated into the drug discovery pipeline to enable the identification of new and better drugs to treat hearing loss.